Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

This study has been completed.
Sponsor:
Collaborators:
Genentech, Inc.
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Vanderbilt University
Information provided by (Responsible Party):
David F. McDermott, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00782275
First received: October 29, 2008
Last updated: August 29, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2016
  Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)